Literature DB >> 7594526

B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors.

S Guerder1, S R Carding, R A Flavell.   

Abstract

B7-CD28 costimulation is essential for the activation of CD4+ T helper cells, mainly by regulating IL-2 and other cytokine production. The requirement for this costimulatory pathway in the activation of CD8+ T cells, however, is still poorly understood. Here we analyzed the role of B7-CD28 costimulation in the differentiation of Ag-specific CTL precursor. We found that the activation of not only IL-2 production but also cytotoxic function in CD8 T cells requires B7 costimulation. The costimulatory signal, which cannot be replaced by exogenous IL-2, is directly implicated in the activation of the lytic machinery in CD8 T cells. Moreover, B7-CD28 costimulation appears to play a critical role in the accumulation of mRNA encoding at least one of the granzymes required for cytolytic function, granzyme B or CTLA-1. The production of IFN-gamma by CD8 T cells, however, does not appear to require costimulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594526

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Requirement for AHNAK1-mediated calcium signaling during T lymphocyte cytolysis.

Authors:  Didi Matza; Abdallah Badou; Mithilesh K Jha; Tim Willinger; Andrey Antov; Shomyseh Sanjabi; Koichi S Kobayashi; Vincent T Marchesi; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-02       Impact factor: 11.205

Review 2.  DNA gene vaccination for HIV.

Authors:  J J Kim; D B Weiner
Journal:  Springer Semin Immunopathol       Date:  1997

Review 3.  Memory T cells in organ transplantation: progress and challenges.

Authors:  Jaclyn R Espinosa; Kannan P Samy; Allan D Kirk
Journal:  Nat Rev Nephrol       Date:  2016-02-29       Impact factor: 28.314

4.  Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens.

Authors:  Pablo Penaloza-MacMaster; Jeffrey E Teigler; Rebecca C Obeng; Zi H Kang; Nicholas M Provine; Lily Parenteau; Stephen Blackmore; Joshua Ra; Erica N Borducchi; Dan H Barouch
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

5.  T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma.

Authors:  W M Mulder; E Bloemena; M J Stukart; J A Kummer; J Wagstaff; R J Scheper
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

6.  Brucella abortus as a potential vaccine candidate: induction of interleukin-12 secretion and enhanced B7.1 and B7.2 and intercellular adhesion molecule 1 surface expression in elutriated human monocytes stimulated by heat-inactivated B. abortus.

Authors:  M Zaitseva; H Golding; J Manischewitz; D Webb; B Golding
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

7.  Opposing effects of CD70 costimulation during acute and chronic lymphocytic choriomeningitis virus infection of mice.

Authors:  Pablo Penaloza-MacMaster; Ata Ur Rasheed; Smita S Iyer; Hideo Yagita; Bruce R Blazar; Rafi Ahmed
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

8.  Preferential use of B7.2 and not B7.1 in priming of vaccinia virus-specific CD8 T cells.

Authors:  Shahram Salek-Ardakani; Ramon Arens; Rachel Flynn; Alessandro Sette; Stephen P Schoenberger; Michael Croft
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  Cross-linking of Fc(gamma)-receptor on monocytes inhibits hepatitis C virus-specific cytotoxic T-lymphocyte induction in vitro.

Authors:  T Kanto; N Hayashi; T Takehara; K Katayama; A Ito; K Mochizuki; N Kuzushita; T Tatsumi; Y Sasaki; A Kasahara; M Hori
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

10.  CD28 costimulation is required for in vivo induction of peripheral tolerance in CD8 T cells.

Authors:  Melanie S Vacchio; Richard J Hodes
Journal:  J Exp Med       Date:  2003-01-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.